ErikAllenImelMD
Endocrinology • Indianapolis, INDiabetes, Osteoporosis & Bone Metabolism Medicine, Parathyroid, Pediatric Endocrinology
Professor, Medicine and Pediatrics, Indiana University School of Medicine
Dr. Imel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
550 University Blvd
Ste 2180
Indianapolis, IN 46202Phone+1 317-843-0000- Is this information wrong?
Education & Training
Indiana University School of MedicineFellowship, Pediatric Endocrinology, 2003 - 2007
University of RochesterResidency, Internal Medicine/Pediatrics, 1999 - 2003
University of Cincinnati College of MedicineClass of 1999
Certifications & Licensure
IN State Medical License 2003 - 2025
NY State Medical License 2003 - 2005- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- American Board of Pediatrics Pediatric Endocrinology
Clinical Trials
- Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Start of enrollment: 2014 Jul 02
- Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. Start of enrollment: 2014 Aug 01
- CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis Start of enrollment: 2019 Dec 18
- Join now to see all
Publications & Presentations
PubMed
- Autosomal dominant osteopetrosis.Lynda E Polgreen, Erik A Imel, Michael J Econs> ;Bone. 2023 May 1
- 2 citationsBurosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.Erik A Imel, Francis H Glorieux, Michael P Whyte, Anthony A Portale, Craig F Munns, Ola Nilsson, Jill H Simmons, Raja Padidela, Noriyuki Namba, Hae Il Cheong, Pisit Pi...> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Oct 18
- Editorial: Rare musculoskeletal disorders: disease mechanisms and therapies.Lothar Seefried, Nathalie Bravenboer, Erik A Imel> ;Frontiers in Endocrinology. 2023 Jan 1
- Join now to see all
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Press Mentions
Burosumab Effects Persist Long-Term for Children with Rare Form of RicketsSeptember 16th, 2020
Burosumab Improves Symptom Relief in Genetic RicketsJuly 5th, 2019
Clinical Trial Improves Treatment of Genetic RicketsMay 18th, 2019- Join now to see all
Grant Support
- FGF23 In Pediatric Phosphate Physiology And X-Linked Hypophosphatemic Rickets.National Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
Professional Memberships
- Member
Hospital Affiliations
Riley Hospital for Children at IU HealthIndianapolis, Indiana
Indiana University Health University HospitalIndianapolis, Indiana
Richard L. Roudebush Veterans Affairs Medical CenterIndianapolis, Indiana
Eskenazi HealthIndianapolis, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
